Improving bioavailability with a novel isotretinoin formulation (isotretinoin-lidose).

Improving bioavailability with a novel isotretinoin formulation (isotretinoin-lidose).
Skin Therapy Lett. 2013 Oct;18(6):1-3
Authors: Tan J, Knezevic S
Abstract
Current practice guidelines recommend administration of oral isotretinoin with high-fat meals, which may pose issues with patient compliance. Isotretinoin-Lidose (Epuris™), approved by Health Canada in November 2012 and scheduled for commercial release June 2013, is based on novel lipid encapsulation technology (Lidose®) to enclose isotretinoin, thereby increasing drug absorption during fasted states. An open label, single dose randomized crossover study demonstrated pharmacokinetic bioequivalence of isotretinoin-Lidose to standard isotretinoin formulations during fed states, with significantly greater absorption during fasting. Isotretinoin-Lidose, may lead to more consistent plasma levels of isotretinoin during variable dietary conditions, providing the potential for enhanced patient outcomes.
PMID: 24305729 [PubMed - in process]

Source: Skin Therapy Letter - October 1, 2013 Category: Dermatology Authors: Tan J, Knezevic S Tags: Skin Therapy Lett Source Type: research